ArticleBrain & spine2026
Fluorescein-guided surgical ablation of spinal dural arteriovenous fistula (SDAVF) is a safe and effective add-on to ensure surgical closure.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Spinal dural arteriovenous fistula (SDAVF) is the most common subtype of spinal arteriovenous lesions. SDAVF often causes intramedullary edema, resulting in ischemic myelopathy and progressive paraplegia over time. Identifying the SDAVF intraoperatively is not always easy. Fluorescein-guided surgical ablation is a technique developed in our department to visualize the fistula in SDAVF enabling secure surgical closure. Research question: To evaluate the efficiency of fluorescein-guided open surgical ligation treatment of SDAVFs. Material and Methods: Single centre retrospective cohort study. Results: 22 patients (male = 18), 34 - 83 years of age were included. Patients presented with gait disturbance (n=22) balance disturbances (n=20), back pain (n=15), and/or radicular pain to the lower extremities (n=13). Fluorescein-guided surgical ablation was applied peri-operatively in all patients. Successful identification of SDAVF was seen in all patients. One had re-surgery; in this patient the fluorescein-guided was not followed and dural leakage was observed. No complication to the add-on procedure was seen. After treatment, 19 patients experienced either complete remission- or some degree of improvement in gait disturbance (RR=0.86 (95% Confidence interval (CI) 0.65-0.97)), balance disturbances ((RR=0.85 (95%CI 0.62-0.97)), back pain ((RR=0.53 (95%CI 0.27-0.79)), and/or radicular pain ((RR=0.69 (95%CI 0.39-0.91)). Rostro-caudal extent of intramedullary edema on Magnetic resonance imaging was reduced by a mean 161 mm (95%CI 129-194) postoperatively. Discussion and Conclusion: Fluorescein-guided open surgical ablation of SDAVF is safe and seems a low cost effective diagnostic add-on with postoperative clinical- and imaging improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.